| Q47759652 | (-)Nicotine inhibits the activations of phospholipases A2 and D by amyloid beta peptide |
| Q44070739 | 4,4(')-Dianilino-1,1(')-binaphthyl-5,5(')-disulfonate: report on non-beta-sheet conformers of Alzheimer's peptide beta(1-40). |
| Q36106834 | Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease |
| Q74250498 | Amino acids within residues 181-200 of the nicotinic acetylcholine receptor alpha1 subunit involved in nicotine binding |
| Q33392254 | Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease |
| Q28287401 | Amyloidogenic hexapeptide fragment of medin: homology to functional islet amyloid polypeptide fragments |
| Q33971304 | Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization |
| Q28648344 | Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study |
| Q46692906 | Attenuation of Abeta deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking. |
| Q36269317 | Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling |
| Q35065815 | Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease |
| Q34121565 | Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? |
| Q44283142 | Change and stabilization of the amyloid-beta(1-40) secondary structure by fluorocompounds |
| Q34251448 | Cholinesterase inhibitors for behavioral disturbance in dementia |
| Q35687034 | Chronic stress and Alzheimer's disease-like pathogenesis in a rat model: prevention by nicotine |
| Q32077222 | Cognitive effects of nicotine |
| Q40925045 | Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation |
| Q37855869 | Computational insights into the development of novel therapeutic strategies for Alzheimer's disease |
| Q58855761 | Conformational Stability of A?-(25?35) in the Presence of Thiazolidine Derivatives |
| Q38005188 | Cotinine: a potential new therapeutic agent against Alzheimer's disease. |
| Q37970511 | Dementia, stroke, and vascular risk factors; a review |
| Q47735746 | Design of peptides undergoing self-catalytic alpha-to-beta transition and amyloidogenesis |
| Q35209288 | Design strategies for anti-amyloid agents. |
| Q81312620 | Designed amyloid beta peptide fibril - a tool for high-throughput screening of fibril inhibitors |
| Q40263828 | Dietary glycemic load and risk of cognitive impairment in women: findings from the EPIC-Naples cohort |
| Q34166256 | Drug development for Alzheimer's disease: where are we now and where are we headed? |
| Q30434143 | Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology |
| Q46446908 | Effect of gelation on the chemical stability and conformation of leuprolide |
| Q57822469 | Effect of smoking cessation on the risk of dementia: a longitudinal study |
| Q32077161 | Effects of nicotine on APP secretion and Abeta- or CT(105)-induced toxicity |
| Q41573423 | Engineering peptides and proteins that undergo alpha-to-beta transitions |
| Q48356437 | Exploration of the mechanism for LPFFD inhibiting the formation of beta-sheet conformation of A beta(1-42) in water |
| Q39516286 | Fullerenolates: metallated polyhydroxylated fullerenes with potent anti-amyloid activity. |
| Q37215765 | Gender differences in the association of smoking and drinking with the development of cognitive impairment |
| Q34207086 | Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease |
| Q37239443 | Highly enantioselective borane reduction of heteroaryl and heterocyclic ketoxime ethers catalyzed by novel spiroborate ester derived from diphenylvalinol: application to the synthesis of nicotine analogues |
| Q34778095 | Immunization treatment approaches in Alzheimer's and prion diseases. |
| Q33712215 | Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model |
| Q42667972 | In silico and in vitro studies to elucidate the role of Cu2+ and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process. |
| Q41996786 | Inflammation and oxidative stress induced by cigarette smoke in Lewis rat brains |
| Q57364071 | Inhibiting, promoting, and preserving stability of functional proteinfibrils |
| Q33514614 | Inhibition of beta-amyloid(1-40) Peptide Aggregation and Neurotoxicity by Citrate |
| Q47744275 | Laminin inhibits A beta 40 fibril formation promoted by apolipoprotein E4 in vitro |
| Q48466917 | Laminin inhibits Abeta42 fibril formation in vitro |
| Q53230710 | Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. |
| Q33894541 | Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors |
| Q64880531 | Natural Compounds for Alzheimer's Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. |
| Q36163354 | Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease |
| Q48275764 | Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation |
| Q38163337 | Neuropathology of cigarette smoking |
| Q48491933 | Neuroprotection in Alzheimer's disease - new strategies for treatment. |
| Q88959335 | Newfound effect of N-acetylaspartate in preventing and reversing aggregation of amyloid-beta in vitro |
| Q32077192 | Nicotine and amyloid formation |
| Q32077110 | Nicotine and its interaction with beta-amyloid protein: a short review |
| Q73634969 | Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons |
| Q44193624 | Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro |
| Q40555290 | Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. |
| Q43233908 | Nicotine reduces the cytotoxic effect of glycated proteins on microglial cells |
| Q36564840 | Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms |
| Q41597454 | Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. |
| Q33919793 | Nicotinic systems in central nervous systems disease: degenerative disorders and beyond |
| Q43035083 | Overcoming synthetic Abeta peptide aging: a new approach to an age-old problem. |
| Q34904386 | Ovine colostrum nanopeptide affects amyloid beta aggregation |
| Q38558352 | Perspectives on Inhibiting β-Amyloid Aggregation through Structure-Based Drug Design |
| Q33702171 | Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease |
| Q47621732 | Primary structure determinants of the pH- and temperature-dependent aggregation of thioredoxin |
| Q41813305 | Protein engineering as a strategy to avoid formation of amyloid fibrils |
| Q33883591 | Secondhand smoke, vascular disease, and dementia incidence: findings from the cardiovascular health cognition study |
| Q53224118 | Smoking and risk of Alzheimer's disease. MIRAGE Study Group. |
| Q43516778 | Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. |
| Q48443000 | Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. |
| Q39832389 | Structurally distinct toxicity inhibitors bind at common loci on β-amyloid fibril |
| Q39622197 | Surface plasmon resonance based biosensors for exploring the influence of alkaloids on aggregation of amyloid-β peptide |
| Q34324800 | TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. |
| Q52144183 | TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. |
| Q87354667 | Targeted studies on the interaction of nicotine and morin molecules with amyloid β-protein |
| Q77134753 | The inhibitory effect of laminin 1 and synthetic peptides deduced from the sequence in the laminin alpha1 chain on Abeta40 fibril formation in vitro |
| Q33887372 | The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited |
| Q39746495 | The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population |
| Q43645419 | The relationship between the aggregational state of the amyloid-beta peptides and free radical generation by the peptides |
| Q55514434 | The role of phenolic OH groups of flavonoid compounds with H-bond formation ability to suppress amyloid mature fibrils by destabilizing β-sheet conformation of monomeric Aβ17-42. |
| Q36622649 | The significance of the cholinergic system in the brain during aging and in Alzheimer's disease |
| Q38088318 | Therapeutic strategies against protein misfolding in neurodegenerative diseases |
| Q58067916 | Transformation of β-sheet structures of the amyloid peptide induced by molecular modulators |
| Q58124865 | Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β-peptide |
| Q35038274 | Unfolding the role of protein misfolding in neurodegenerative diseases |
| Q28546473 | Virtual and In Vitro Screens Reveal a Potential Pharmacophore that Avoids the Fibrillization of Aβ1-42 |
| Q34193248 | beta-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease |
| Q38831113 | Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review |